TOR Pathway

Følg
Scientist examining extended-lifespan yeast cells under microscope with rapalink-1 cancer drug vial, illustrating anti-aging breakthrough.
Bilde generert av AI

Next-generation cancer drug shows anti-aging effects in yeast

Rapportert av AI Bilde generert av AI Faktasjekket

Researchers at Queen Mary University of London have found that rapalink-1, an experimental TOR inhibitor being investigated for cancer therapy, extends the lifespan of fission yeast. The study also uncovered a role for agmatinases in regulating the TOR pathway through a metabolic feedback loop, suggesting potential links between diet, gut microbes, and aging.

Dette nettstedet bruker informasjonskapsler

Vi bruker informasjonskapsler for analyse for å forbedre nettstedet vårt. Les vår personvernerklæring for mer informasjon.
Avvis